ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enlonstobart

Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageEnlonstobart: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 16, 202315 company-led studies, 11 open or runningNext primary completion: Jan 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only1410 open or runningphase 3since Jan 16, 2023Feb 20, 2019Apr 2027phase 2 · NCT06136988
Shanghai Runshi Pharmaceutical Technology11 open or runningphase 2since Nov 9, 2023Nov 9, 2023Jan 30, 2027phase 2 · NCT06132217

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shanghai Runshi Pharmaceutical Technology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2023Named enlonstobartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, SG001
  2. Nov 9, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06132217 · 168 planned · China

Ahead

  1. Jan 30, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06132217

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

The one study Shanghai Runshi Pharmaceutical Technology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06132217Advanced Solid Tumor · China2Not yet recruitingJan 30, 2027168

How it is read

Names in the registry

  • “SG001”, 8 entries
  • “Enlonstobart”, 3 entries
  • “SYS6041, enlonstobart, bevacizumab”, 1 entry
  • “Enlonstobart injection”, 1 entry
  • “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.